Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Indoco Remedies declares receipt of Approval of its ANDA for Succinylcholine Chloride Injection USP 200 mg/10 ml (20 mg/ml) Multi-portion vial, restoratively equal to the Reference Listed Drug (RLD) Quelicin Injection of Hospira, Inc.
Succinylcholine Chloride Injection is shown as an aide to general sedation, to encourage tracheal intubation, and to give skeletal muscle unwinding during medical procedure or mechanical ventilation.
The US showcase size of Succinylcholine Chloride Injection is of 72 million USD (6 million vials), according to IMS information for the year finishing March, 2020.
The item is being utilized for certain patients tainted with Corona infection (COVID-19).
Remarking on this positive result, Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd. stated, “The receipt of this USFDA endorsement, in a record time of only 4 months from the date of documenting ANDA, is extremely reassuring. It carries a huge chance to Indoco to serve the patients in these difficult occasions.”
Portions of INDOCO REMEDIES LTD. was last exchanging BSE at Rs.209.8 when contrasted with the past close of Rs. 215.8. The all out number of offers exchanged during the day was 674 in more than 110 exchanges.
The stock hit an intraday high of Rs. 216.45 and intraday low of 208.1. The net turnover during the day was Rs. 142423.
